Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma

• Published in: Hematology (Luxembourg) 2022-12, Vol.27 (1), p.1272-1281
• Main Authors: Deng, Jili, Mi, Lan, Wang, Xiaopei, Zhu, Jun, Zhang, Chen, Song, Yuqin
• Format: Article
• Language: English
• Subjects: DLBCL; Primarybreastlymphoma; prognosis; relapse
• ISSN: 1607-8454; 1607-8454
• DOI: 10.1080/16078454.2022.2150389

: A primary breast lymphomais a rare form of extranodal lymphoma type. We aimed to analyze prognosticriskfactors and explore relapse factors in primary breast diffuse large B cell lymphoma (PB-DLBCL). : From November 2003 to September 2020, sixty-three patients from two medical centers newly diagnosed with PB-DLBCL patients were analyzed retrospectively. : The median age was 52, and >50% of patients were post-menopausal. The international prognostics index (IPI) (0-1) was mainlyin the low-risk group (84%), and there were four patients with stage IV (6%) who had bilateral breast involvement. With a median follow-up time of 4.92 years (3.17-8.00), five-year overall survival (OS) and progression-free survival (PFS) were 78.9% and 67.1%, respectively. Univariate and multivariate analyses showed that elevated erythrocyte sedimentation rate (ESR) and B symptoms were independent adverse prognostic risk factors for OS, whereas bilateral breast involvement was unfavorable for PFS. Disease recurrence and relapse occurred in 40% (25/63) patients, mainly in the breast, followed by the central nervous system (CNS) and skin/soft tissue. : This is the first study to explore the prognostic risk factors and relapse factorsof PB-DLBCL in a relatively large Chinese PBL cohort. Local breast and CNS recurrence after standard R-CHOP treatment were the main issues we are facing now.